Equillium Inc (EQ) - Total Liabilities
Based on the latest financial reports, Equillium Inc (EQ) has total liabilities worth $3.57 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Equillium Inc cash flow conversion to assess how effectively this company generates cash.
Equillium Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Equillium Inc's total liabilities have evolved over time, based on quarterly financial data. Check Equillium Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Equillium Inc Competitors by Total Liabilities
The table below lists competitors of Equillium Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EDAP TMS SA
NASDAQ:EDAP
|
USA | $59.58 Million |
|
TON Strategy Co
NASDAQ:TONX
|
USA | $22.42 Million |
|
China National Accord Medicines Corp Ltd
SHE:200028
|
China | HK$29.01 Billion |
|
Bank Negara Indonesia Tbk
JK:BBNI
|
Indonesia | Rp1036.47 Trillion |
|
Jiayin Group Inc
NASDAQ:JFIN
|
USA | $3.61 Billion |
|
Penta Teknoloji Urunleri Dagitim Ticaret AS
IS:PENTA
|
Turkey | TL8.70 Billion |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
USA | $24.04 Million |
|
Axcen Photonics
TWO:6530
|
Taiwan | NT$64.67 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Equillium Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Equillium Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Equillium Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Equillium Inc (2017–2024)
The table below shows the annual total liabilities of Equillium Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.54 Million | -76.60% |
| 2023-12-31 | $27.96 Million | -39.85% |
| 2022-12-31 | $46.48 Million | +145.92% |
| 2021-12-31 | $18.90 Million | +21.36% |
| 2020-12-31 | $15.57 Million | +13.75% |
| 2019-12-31 | $13.69 Million | +514.50% |
| 2018-12-31 | $2.23 Million | -76.31% |
| 2017-12-31 | $9.40 Million | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as we… Read more